LB Pharmaceuticals closes $75M Series C as it begins PhII schizophrenia trial
LB Pharmaceuticals, a schizophrenia biotech developing a new version of a decades-old medicine, has closed a $75 million Series C raise and it began a Phase II trial last month, a source familiar with the company confirmed to Endpoints News.
The New York City biotech has raised a total of about $122 million since it was formed, per the source. The company had raised about $35 million last summer and reached its ultimate $75 million Series C target this month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.